Your Article Summary
See Latest ArticlesSouthwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer
Gynecologic Oncology, 06/30/09
Smith HO et al. - Both the overall trial outcome, and specifically the excessively severe systemic toxicity of this regimen would prevent its future development in this exact form. The provocative PFS in a subset of individuals should encourage the development of alternative strategies designed to optimize the delivery of regional therapy in ovarian cancer management.
Related Articles
Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09
Relevance Score: 72%
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 70%
Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09
Relevance Score: 70%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 70%
New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09
Relevance Score: 70%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09